Who are Pegasys(Roche)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rosiglitazone and Pegasys/Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegasys-roche.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Pegasys(Roche) — Competitive Intelligence Brief

Pegasys(Roche) (Pegasys(Roche)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated interferon alfa-2a. Area: Virology / Oncology.

phase 3 Pegylated interferon alfa-2a Interferon alfa receptor (IFNAR) Virology / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pegasys(Roche) (Pegasys(Roche)) — Third Affiliated Hospital, Sun Yat-Sen University. Pegasys is a pegylated interferon alfa-2a that activates innate immune responses to suppress viral replication and inhibit cell proliferation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pegasys(Roche) TARGET	Pegasys(Roche)	Third Affiliated Hospital, Sun Yat-Sen University	phase 3	Pegylated interferon alfa-2a	Interferon alfa receptor (IFNAR)
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated interferon alfa-2a class)

Third Affiliated Hospital, Sun Yat-Sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegasys(Roche) — Competitive Intelligence Brief. https://druglandscape.com/ci/pegasys-roche. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab